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The quality by design approach was introduced to the biopharmaceutical indus-
try over 15 years ago. This principle iswidely implemented in the characterization
of monoclonal antibody production processes. Anyway, the early process phase,
namely the inoculum expansion, was not yet investigated and characterized for
most processes. In order to increase the understanding of early process parame-
ter interactions and their influence on the later production process, a risk assess-
ment followed by a design of experiments approach was conducted. The DoE
included the critical parameters methotrexate (MTX) concentration, initial pas-
sage viable cell density and passage duration. Multivariate data analysis led to
mathematical regression models and the establishment of a designated design
space for the studied parameters. It was found that the passage duration as well
as the initial viable cell density for each passage during the inoculum expansion
have severe effects on the growth rate and viability of the early process phase.
Furthermore, the variations during the inoculum expansion directly influenced
the production process responses. This carry-over of factor effects highlights the
crucial impact of early process failures and the importance of process analysis
and control during the first part of mAb production processes.
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1 INTRODUCTION
The Quality by Design (QbD) principle is a risk-based
approach to pharmaceutical development and manufac-
turing [1]. It emerged in 2004 with the Current Good Man-
ufacturing Practice for the 21st century initiative [2]. Based
on this, the United States Food and Drug Administra-
tion (FDA) launched a guidance protocol for the biophar-
maceutical industry. This guidance consists of the report
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PRACTICAL APPLICATION
The inoculum expansion was assessed as a criti-
cal part of the mAb production process by exam-
ination of critical process parameters in a design
of experiments approach. Our research resulted
in the definition of a designated design space
and new feedback strategies for a robust process
control. This highlights the importance of early
process understanding and investigation, while
marking the first step towards a full process char-
acterization regarding quality by design principles.
Implementing the conducted concept in the pro-
cess development was thereby shown to be crucial
for the studied process as well as similar cell cul-
ture processes.
PAT – A framework for Innovative Pharmaceutical Manu-
facturing and Quality Assurance [3] and the International
Conference of Harmonisation (ICH) guidelines Q8 Phar-
maceutical Development,Q9Quality RiskManagement and
Q10 Pharmaceutical Quality Systems [4–6].
Before introducing this guidance the pharmaceutical
industry used a traditional approach for process devel-
opment and regulation: A rigid manufacturing process
with batch to batch quality controls and no methodical
connection between process, product and clinical applica-
tion. The QbD paradigm, imposed by the ICH guidelines,
was defined as “a systematic approach to development
that begins in predefined objectives and emphasises prod-
uct and process understanding and process control based
on sound science and quality risk management” [4]. The
objective of this approach is to “build quality into the prod-
uct” rather than “testing quality into the product” [7, 8].
Thereby manufacturers can reduce the post-commercial
filings for process changes, leading to greater flexibility in
biopharmaceutical production and quality control. A gen-
eral roadmap for successful implementation of the QbD
philosophy is shown in Figure 1.
The streamlined operation starts with the product and
process definition, identification of process parameters
and a general risk assessment, often using the Failure
Mode and Effect Analysis (FMEA) [9, 10]. Subsequent pro-
cess characterizations are typically performed in quali-
fied scaled-down models, using a Design of Experiments
approach to set up conclusive experiments [11, 12]. An anal-
ysis of the compiled results leads to the definition of a des-
ignated Design Space [13]. The FDA defines Design Space
as “the multidimensional combination and interaction of
input variables that have demonstrated to provide assur-
ance of quality” [4].
Thereby, design space can be described as the acceptable
range of process parameters, which is located in a broad
characterisation range and inherits the operating range
with optimal set points.Workingwithin the defined design
space is therefore not considered to be a process change
and hence needs no further validation, resulting in cost
savings and the maintenance of a steady workflow.
This work will focus on the QbD implementation of
a monoclonal Antibody (mAb) production process using
a Chinese Hamster Ovary (CHO) cell cultivation process
[14, 15]. Concrete QbD case studies, like the CMC Biotech
Working Group for mAb production processes and the fol-
lowing downstream part are published [16]. Yet, reports on
the QbD implementation on early process steps, namely
the inoculum expansion, are still limited. It consists of
multiple cell passages, which involve the transfer of a
defined cell number into fresh culture medium. By pas-
saging with specific intervals the inoculums is expanded,
while maintaining the cells in a healthy and actively grow-
ing state [17]. Thereby the predefined cell concentration
for inoculation of the production process is achieved. This
early phase of said processes is still not as frequently mon-
itored and regulated as the production part in larger biore-
actors and often falsely treated as a “black box” with no
crucial impact on the following process. The critical impact
of early phase parameters was not yet investigated thor-
oughly and is therefore not fully understood.As envisioned
by the ICH guidelines, the QbD philosophy should be
applied throughout the entire lifecycle of a biopharmaceu-
tical product [4, 18]. This work will therefore create a link-
age between process parameters of the inoculum expan-
sion and process performance of the production process.
A schematic overview of the process is shown in Figure 2.
2 MATERIALS ANDMETHODS
2.1 Cell line and material
For this study a DG44 CHO suspension cell line produc-
ing an IgG1 monoclonal Antibody (mAb) was used (Sarto-
rius Stedim Cellca GmbH). Cells were cultivated in shake
flasks (Corning, USA) in a Heracell 240 CO2 Incubator
(Thermo Scientific, USA) using a MaxQ CO2 Plus shaker
platform (Thermo Scientific, USA). The cultivation was
performed in proprietary and chemically defined cell cul-
ture media, all part of the Sartorius Stedim Cellca medium
platform. The inoculum expansion was performed using
stock medium (SM), whereas the production process used
production medium (PM). Additionally, two feeds were
used during the production process. Macro nutrients (e.g.
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F IGURE 1 Schematic strategy for
implementation of QbD and determination of
a process design space in a
biopharmaceutical production process. CPP,
critical process parameter; CQA, critical
quality attribute; DoE, design of experiments;
QTPP, quality target product profile
F IGURE 2 Schematic representation of the process workflow of monoclonal antibody cell cultivation in larger scale
glucose) were added using feed medium A (FMA), while
micro nutrients (e.g. amino acids) were supplemented
using feed medium B (FMB) (Sartorius Stedim Cellca
GmbH, Germany).
For the first passage of inoculum expansion a cryo vial,
containing 1 mL CHO suspension (30 × 106 cells/mL),
was thawed and transferred to a 15 mL Falcon tube (Sarst-
edt, Germany) with 10 mL stock medium. The suspension
was centrifuged at 190 x g for 3 min using a Microstar17
centrifuge (VWR International, USA). After removal of
the supernatant, the pellet was resuspended in 10 mL
pre-warmed (36.8◦C) stock medium and transferred to
a 500 mL shake flask with 140 mL pre-warmed stock
medium. The inoculum expansion was conducted over
16 days at 36.8◦C and 7.5% CO2 with a shaking rate of
120 rpm. Cells were passaged by centrifugation of the
needed amount of cell suspension, removal of the super-
natant and resuspension in fresh stock medium to the ini-
tial passage viable cell density (VCD).During the first three
passages, the required amount of methotrexate (MTX) was
added to the stock medium. From the second passage,
125 mL shake flasks with a working volume of 25 mL were
used for the experiments.
The production process was performed in 125 mL shake
flasks with 25 mL pre-warmed production medium. All
production cultivations were inoculated to an initial viable
cell density of 0.3 × 106 cells/mL and run over 8 days with
daily feeds (1% feed medium A, 0.1% feed medium B) from
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day 3. Due to the cultivation in shake flasks the pH and
the dissolved oxygen were not controlled, yet the process
was previously analyzed and shown to be reproducible and
comparable to bioreactor cultivations of different scales.
To improve the comparability all experiments were simul-
taneously conducted in the same incubator with identical
process conditions.
2.2 Analytics
Samples were taken daily during the inoculum expan-
sion as well as during the production process. Viable cell
densities and viabilities were measured using a Cedex
HiRes (Roche Innovatis, Swiss) with a 1:2 dilution in 10 %
phosphate-buffered saline (PBS). Growth rates of the pro-
duction process were calculated by linear regression of the
natural logarithm of viable cell densities against culture
duration. The inoculum growth rate relates to the respec-
tive last passage of every inoculum expansion (N-1-step),
in order to ensure optimal comparability of the examined
factor effects. Viabilities were calculated as average over
the culture duration for the inoculum expansion as well as
the production process. The mAb titer was analyzed dur-
ing the production process by using the Cedex Bio (Roche,
Swiss). Therefore, cell separation was performed by cen-
trifugation for 5min at 190 x g. Specific antibody titers were
calculated by dividing the final antibody titer by the inte-
gral viable cell concentration over the entire production
process duration.
2.3 Failure mode and effect analysis
(FMEA)
The risk assessment was performed using the FMEA
approach [9]. The FMEA divides the potential risk into
three main factors. The Probability (P) evaluates the like-
lihood of a possible failure mode. Failure impact on the
system and the product are assessed by the Severity (S). In
addition, theDetection (D) assesses the possibility to detect
and correct a failure mode. These factors were rated on a
scale between 1 and 5 individually for each process param-
eter.Multiplication of these ratings resulted in theRisk Pri-
ority Number (RPN) for each respective parameter.
2.4 Design of experiments (DoE)
The design and analysis was performed using theDoE soft-
ware MODDE 12 (Umetrics, Sartorius Stedim Data Ana-
lystics, Germany). The three parameters with the high-
est RPN during the risk assessment were used as factors
(F1 =MTX concentration, F2 = passage duration, F3 = ini-
tial passage viable cell density) for a central composite
designwith three centre-point runs. The resulting design is
illustrated in the supplements. Hereinafter, the factor set-
tings are described as 0 for centre-point level and –1/1 for
the low and high levels of the full factorial cube, respec-
tively. The additional levels for the star of the central com-
posite design are described as –2 and 2.
The initial viable cell density of each passage was var-
ied equally between 0.1 and 0.3 × 106 cells/mL with a
step size of 0.05 × 106 cells/mL, while the MTX con-
centration was varied between 0 and 30 nM with a step
size of 7.5 nM. The passage duration was varied with-
out any additional level between 2, 3/4 and 5 days with
a constant total inoculum expansion time of 16 days. A
passage duration lower than –1 level was not possible,
because shorter passages than 2 days did not result in
the minimum viable cell number needed for sufficient
inoculum expansion. Also the total duration of all exper-
iments was preserved at 16 days. According to the pro-
cess development, this is the time needed to expand the
inoculum to the minimum viable cell number for inocu-
lation of larger production bioreactors. Therefore, a plane
star was applied in this design, which resulted in a total of
15 runs.
All 15 runs were cultivated simultaneously in the
same incubator. To improve the comparability of the
runs, one vial thaw and centre-point passage one was
used to inoculate the following 15 experiments under
described levels. The factor changes were implemented
on every seed step from the second passage onwards.
Also, all runs respective last passage was run over 3 days,
to compare the final growth rate and enable production
process inoculation on the same day. Passage duration
centre-point runs were passaged every 3-4 days, resulting
in a total of five inoculum expansion steps. The –1 level
runs were passaged every 2 days, the 1 level runs every
5 days, resulting in a total of 7 and 4 passages respectively
(see Figure 4). An overview of the experimental set up and
the explained numerical coding of the parameter levels
are depicted in the supplements. Six different responses
were analysed: Inoculum viability, inoculums growth rate,
production viability, production growth rate, total mAb
titer and specific mAb titer. The responses were predicted
by using the following model:









+ 𝑝7𝐹1𝐹2 + 𝑝8𝐹1𝐹3 + 𝑝9𝐹2𝐹3
Here, 𝑅𝑖 is one of the six responses, p0 is the intercept,
pj are the coefficients of the factors F1, F2 and F3. Fac-
tors whose coefficient has the value zero in its confidential
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F IGURE 3 Ishikawa diagram for the inoculum expansion. Bold parameters were determined as critical and therefore examined during
this study
F IGURE 4 Viable cell densities during the inoculum expansion for experiments with –1/0/1 levels for the passage duration. Cells were
split to 0.2 × 106 cells/mL for each passage
interval are regarded to have no significant influence on
the response and are therefore removed from the model.
2.5 Multivariate data analysis (MVDA)
Multiple linear regression (MLR) was used to fit the math-
ematical model. Various model statistics were investigated
in order to evaluate the conducted model. The R-squared
(R2) term is the fraction of the variation of the response
explained by the model. The adjusted R-squared (R2adj)
term is adjusted for the degrees of freedom of the model.
𝑅2 = 1 −
∑𝑛
𝑖 = 1 (𝑦𝑖 − ?̂?𝑖)
2
∑𝑛
𝑖 = 1 (𝑦𝑖 − ?̄?)
2






) 𝑛 − 1
𝑛 − 𝑝
Here, 𝑦𝑖, ?̂?𝑖 , and ?̄? are the measured data, the predic-
tion of calibration data and themean of themeasured data,
respectively; n is the number of measurement points and
p the number of parameters. Statistical accuracy of future
predictions of themodel is estimated by theQ-squared (Q2)
term. If the y data are not used for calibration, then the Qš
is calculated as follows.
𝑄2 = 1 −
∑𝑛
𝑖 = 1 (𝑦𝑖 − ?̂?𝑖)
2
∑𝑛
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The model p-value represents the significance of the fit-
ted model. It tests the null hypothesis, that the coefficient
is equal to zero, for each term. Here, the p-value belongs
to an f-test, which compares an intercept-only model (just
a constant y = const) with the model under consideration
(𝑅𝑖). The tested null hypothesis is that a fit of the intercept-
onlymodel and themodel𝑅𝑖 are equal. The reproducibility
r compares the replicate variability to the overall variability
of the experimental data.
𝑟 = 1 −𝑀𝑆𝑝𝑒∕𝑀𝑆𝑡𝑜𝑡
Here, 𝑀𝑆𝑝𝑒 is the mean square of the pure error and
𝑀𝑆𝑡𝑜𝑡 the total mean square of y. A reproducibility value
of 1 signifies perfect reproducibility.
3 RESULTS AND DISCUSSION
In order to investigate possible influences of the inocu-
lum expansion on the production process, critical pro-
cess parameters must be identified and assessed based
on a design of experiment to establish a design space for
this early process step. During this evaluation the effects
of the inoculum expansion on the production process
must be considered as target values for a high quality
process.
3.1 Risk assessment
All possible process parameters were listed in an Ishikawa
diagram (Figure 3), which depicts potential root causes
for specific failure events during the studied process. The
parameterswere categorized in different parts of the inocu-
lum expansion, namely the vial thaw, the medium and the
process.
Historical data as well as profound process understand-
ing were used to rank process parameters according to
their potential risks for the process robustness and produc-
tivity. Hence, a FailureMode and Effect Analysis approach
was used. The probability, severity and detectability of each
parameter were rated individually and multiplied, result-
ing in the respective risk priority number.
Some specific parameters, like general media compo-
sition and cell line, were not taken into account during
the risk assessment because they were profoundly anal-
ysed and optimized during process and media develop-
ment. Others like the temperature and incubator CO2 con-
centration were ruled out during risk assessment due to
the optimized control of the used incubator. This results
in low failure probability and high detectability of possi-
ble failure modes like loss of CO2 pressure. Since the pro-
cess was shown to be replicable in scaled down bioreac-
tors, parameters like the flask scale were also known to be
non-critical for the process [19]. The threshold RPN to con-
sider a parameter to be critical for the system- and product
robustness was determined to be 15, representing a mod-
erate to significant risk of at least two of the FMEA fac-
tors. Critical process parameters identified in this way are
shown in bold in Figure 3 and are represented in Table 1.
The complete FMEA table is summarized in the supple-
ments.
The methotrexate concentration has a significant
influence on the antibody production and severe toxic
effects on the CHO cells (Severity = 5) [20]. A failure
in adjusting the MTX concentration within the stock
medium is furthermore not easily detectable during the
later process steps (Detection = 4). Therefore, the MTX
concentration was considered a critical parameter and
used as factor F1 in the DoE, despite the low failure
probability (Probability = 1) due to standard operation
procedure and good laboratory manufacturing practise.
For the passage duration (F2), the balance between too
short passages, leading to an insufficient viable cell density
for the expansion of the seed steps, and too long passages,
leading to consumed nutrients, can be a critical aspect
(Severity = 3). Also this parameter can be of special inter-
est because other failures in the system, e.g. the prepa-
ration of the production bioreactor, can lead to a delay
in the process and longer passage duration. Likewise, the
tight schedule in production and a failure in seed culture
could lead to shortened time available for the new inocu-
lum expansion (Probability= 3). In reality, the layout of the
inoculum expansion can also be dependent on other fac-
tors likeworking hours and days in the industry. Therefore,
the understanding of the impact of the passage duration in
combination with the other critical process parameters is
needed to define a robust design space for the inoculum
expansion.
Failures in the initial passage viable cell density (ini-
tial passage VCD) would be detected quickly; however, a
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TABLE 1 Failure mode and effect analysis (FMEA) results for the examined parameters
Probability Severity Detection RPN
MTX concentration 1 5 4 20
Passage duration 3 3 2 18
Initial passage VCD 2 2 4 16
Probability, severity and detection were individually rated between 1 and 5. In words, 1 represents no potential risk, 3 moderate/controllable risk and 5 significant
risk
readjustment is virtually impossible without time consum-
ing preparation of new shake flasks and medium (Detec-
tion = 4). The readjustment of the passage viable cell den-
sity is also logistically impossible in a scaled-up approach
with seed bioreactors due to the preparation of the needed
reactor. The probability of a failure was considered to be
low yet possible, due to rare inaccuracies during the pas-
sages (Probability = 2). It was also considered to show a
direct non-severe impact on the nutrient consumption and
thereby the growth rate and viability (Severity= 2). There-
fore, the initial passage VCD is used as factor F3.
3.2 DoE concept and implementation
The ICH Guidelines determined the implementation of
a Design of Experiments approach to investigate the sin-
gle and combined influence of critical process parame-
ters. Accordingly, theMTX concentration (F1), the passage
duration (F2) and the initial passage viable cell density (F3)
were combined in a central composite DoE.
The initial passage VCD as well as the MTX concentra-
tion were varied on a five level scale (–2,–1,0,1,2), while
the passage duration could only be varied on three levels
(–1,0,1). As explained in the Material and Methods, a pas-
sage duration lower than 2 days (–1 level) did not result
in the minimum viable cell number needed for sufficient
inoculum expansion. Longer passages than 5 days (1 level)
did not fit in the experimental design and total inocu-
lum expansion duration of 16 days. Furthermore, previ-
ous experiments show that inoculum expansion passages
of more than 5 days result in severe negative effects due to
consumed nutrients. The centre-point experiment on level
0 was conducted with four passages of 3 days and one pas-
sage of 4 days to fulfil the total duration of 16 days. The
respective last passage of every experiment was cultivated
3 days before inoculation of the production processes. Fig-
ure 4 visualizes the passage duration principle by plotting
the viable cell densities of three different runs (–1, 0, 1).
During the inoculum expansion the growth rates and
cell viabilities of each experiment were monitored as
responses for the early process steps. The growth rate was
calculated for the respective last passage of the inoculum
expansion. These responses provide specific information
on the inoculum expansion culture. The growth rate deter-
mines when the minimum viable cell number for inocula-
tion of the next passage or the production bioreactor will
be reached. An inoculum expansion with a high prolifer-
ation rate also shortened the lag phase of the production
process. Therefore, improvements in the inoculum growth
rate could lead to reduced process time and production
costs. A maximized viability during the inoculum expan-
sion is crucial for the maintenance of the culture and the
successful inoculation of the production bioreactor.
In order to investigate the influence of the determined
inoculum expansion process parameters on the later pro-
cess steps, all inoculum cultures were used to inoculate
scaled-down production processes. These were simultane-
ously cultivated at standard conditions and sampled daily.
The growth rates, average viabilities and the antibody titer
were monitored as responses for the later state of the pro-
cess. To obtain an optimal production process all of these
responses should be maximized. A high growth rate leads
to an early reach of an acceptable VCD for sufficient anti-
body production rates. An optimal viability ensures the
maintenance of the culture during the entire production
process. Moreover, the high viability is important to min-
imize the amount of cell debris, DNA and HCPs that are
released to the medium and have to be removed expen-
sively during the downstream part. To provide a prof-
itable process the final product titer obviously has to be
maximized. Additionally to the antibody titer, the specific
titer was investigated as a response. It elucidates the cell
specific productivity for the studied culture conditions.
Thereby, it is possible to establish a specific production
control between optimized growth and productivity. Typi-
cally, quality attributes in the biopharmaceutical industry
include the quality of the product, such as the bioactivity
or the glycosylation of the antibody. Yet, we concluded that
the quality attributes for the inoculum expansion in our
experimental set up have to be the condition of the final
inoculum. That includes the growth rate, viability and also
the productivity of the following production process. These
were rated as sufficient responses for ameaningful conclu-
sion regarding the inoculum expansion performance and
its direct influence on the production.
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F IGURE 5 Factor (parameter) and its interaction effect plots for the inoculum expansion and production process responses. Not shown
parameters as well as parameters whose confidential interval includes zero were determined to have no significant effect on the respective
response (Pas, passage duration, MTX, TX concentration, VCD, initial passage viable cell density)
3.3 Multivariate data analysis
Multiple linear regression (MLR) was used to analyse the
factors and evaluate the responses (inoculums viability,
inoculums growth rate, production viability, production
growth rate, total mAb titer and specific mAb titer) by
fitting mathematical models. The regression models were
used to determine effects of the studied factors (process
parameters) and their interactions. Factors, which include
zero in its confidential interval, are insignificant and hence
eliminated from the corresponding model. The resulting
main effects are plotted in Figure 5. Most of the parame-
ters and parameter interactions show negative coefficients
for the prediction of the growth rates and viabilities of the
inoculum expansion and the production process as well as
the total mAb titer. The passage duration shows the most
considerable influence, both as a linear effect (Pas) for all
responses as well as a non-linear effect (Pas*Pas) for the
inoculum responses. Furthermore, it shows strong effects
in the interactionwith the initial passage viable cell density
(VCD*Pas). Its negative coefficient on the growth rate and
viability can be explained by the consumption of impor-
tant nutrients as well as the aggregation and stress of cells
at higher cell densities during the inoculum expansion.
The fact that those effects are still detectable in the pro-
duction process, supports the hypothesis that parameter
effects from the early process steps indeed carry over to the
production process. This certainly shows the severe influ-
ence of the inoculum expansion on later process steps. A
slightly lower but still significant negative coefficient on all
responses was observed for the initial passage viable cell
density (VCD), which can also be explained by its strong
connection to the nutrient consumption and cell interac-
tion from the beginning of every passage. The MTX con-
centration (MTX) only showed negative linear effects on
the production process responses, which again underlines
the importance of early process monitoring and control
strategies.
Negative coefficients regarding the total mAb titer can
be explained by the connection between viable cell den-
sity and total product concentration. Evidently, a higher
cell count during the cultivation leads to an increased titer.
Therefore, the explained negative effects on the growth
rate influence the total mAb titer, which is why the spe-
cific mAb titer was calculated and used as an additional
response. In contrast to the discussed responses, the stud-
ied parameters show consistently positive effects on the
cell specific mAb titer. This could signify that cells, grow-
ing under suboptimal cultivation conditions in regard to
growth and viability, show an increased specific anti-
body production. Again, the passage duration (Pas) and
its interaction with the initial passage viable cell density
(VCD*Pas) show the most significant effects, supporting
the concept of counteraction between optimal growth and
specific productivity. Also, the MTX concentration (MTX)
shows a comparatively high effect on the specific mAb
titer, indicating the importance of balance between selec-
tion pressure and ideal cultivation conditions.
To investigate the meaningfulness of the regression
models, various model statistics were analysed. The full
model statistics table is shown in the supplements. All
models show a good fit to the experimental data with R2
and R2adj values mostly over 0.9. The Q2 term, represent-
ing the predictive power of themodel and its ability to gen-
eralize to unseen data, is also sufficient for all responses
with the lowest value for the production viability at 0.62.
Model significance, represented by the p-value, shows a
great meaningfulness for all responses with values close
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F IGURE 6 Observed versus predicted plots for the inoculum expansion and production process responses
F IGURE 7 Response contour plots showing results for inoculum expansion and production process responses
to zero. Also the reproducibility of the model is ensured
for all responses with reproducibility values all over 0.7. In
summary, the model statistics elucidate well fitted regres-
sion models for all selected responses. Also, the predictive
power as well as the reproducibility is sufficient for the
analysis of parameter effects. Since themodel shall be used
for future predictions and the establishment of a design
space, the predictive power is particularly important. Thus,
the observed response values were plotted against the pre-
dicted response values, to enable further insights on the
model and possible outliers. The resulting observed vs pre-
dicted plots for all responses are shown in Figure 6.
For the evaluated responses the plots show an overall
strong predictive power. Furthermore, this plot allows an
explanation for the comparatively low model statistic val-
ues of the production viability. It can show possible indi-
vidual outliers as well as the biggest overall spread of data
points. These were further investigated by analysis of the
response residuals and the normal probability of distribu-
tion, which implied no significant outliers. In summary,
the models were verified by analysis of the model statis-
tics and the observed vs. predicted plot. Overall well fit-
ted models with strong predictive power and a great repro-
ducibility were determined.
The observed interaction effects of the passage duration
and the initial passage VCD were further investigated by
analysis of the response contour plots shown in Figure 7.
These provide a two-dimensional illustration of the
combined parameters and their impact on the respective
response. All represented growth rates and viabilities as
well as the total mAb titer show similar contour plots.
The estimated optimum for these responses is close to the
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F IGURE 8 Determined design space for the inoculum expansion and production process viability/growth rate and the antibody titer with
colour coded probability of failure
–1 level for the passage duration and slightly higher than
the 0 level for the initial passage VCD. Passage durations
lower than –1 level were practically not possible because
passages shorter than 2 days did not result in the mini-
mum viable cell number needed for sufficient inoculum
expansion. That is why the passage duration levels could
not be shifted further towards the estimated optimum.
A passage duration longer than the 0 level resulted in
worsened response values for all said responses.
Furthermore, the non-linearity as well as the interac-
tion of the parameter effects, which were observed in the
effect plot, is detailed in the contour plots. This can be seen
particularly in the inoculum viability contour plot with an
anticipated optimum at –1 level for the passage duration
and 1 level for the passage VCD. The presence of a pre-
dictable optimum underlines the effect interaction of fac-
tors. Shown similarities between the inoculum expansion
and the production process responses also underline the
hypothesis that the early process steps have a considerable
influence on the production process. These investigations
highlight the importance of a sound monitoring and con-
trol strategy for the shown parameters.
The total mAb titer was shown to be the most robust
response in relation to the passage duration and the initial
passage VCD. Again, the optimum was anticipated below
–1 level for the passage duration. Besides that, the contour
plot shows a substantial robust working area with no con-
siderable loss in antibody titer. That is likely due to the cell
line and process development, which was focused on the
optimization of the produced antibody titer.
In contrast, the specific antibody titer shows an esti-
mated optimum at the upper end of the examined space.
Increasing passage duration as well as increasing initial
passage viable cell density equally improved the specific
productivity of the cells. Anyway, the increased produc-
tivity could still not compensate the negative effects on
the growth rate and therefore the total cell number and
final product titer. Taking only the studied factor effects
into account, it was shown to be yet more worthwhile to
improve the growth and viability of the cells in order to
increase the total mAb titer.
Therefore, the respective growth rate and viability
responses as well as the total mAb titer response were used
for further investigation. On that basis a design space for
the studied process was calculated. Monte Carlo simula-
tions were used to compile the needed probability statis-
tics. The resulting design space is shown in Figure 8. It
visualizes the region in the experimental design where all
response specifications are fulfilled with given probabili-
ties. These specifications were experimentally accounted
and adjusted with profound process knowledge which was
expanded during this study.
A robust design space, marked in green, was deter-
mined around the –1 level for the passage duration and 0
level for the initial passage viable cell density. Increasing
MTX concentration shows a negative effect on said design
space. The set standard operation for the passage dura-
tion is located at the boundary of the acceptable proba-
bility values. Consequently, it would be beneficial for the
process safety to either decrease the MTX concentration to
broaden the design space or to shorten the passage dura-
tion to shift the process further towards the design space
midpoint. Mathematical optimization of the three param-
eters resulted in the following optimal set points. The pas-
sage duration and the MTX concentration should there-
fore be decreased to 2 days and 7.5 nM, while the initial
passage viable cell density should be slightly increased to
0.225 × 106 cells/mL.
206 BÖHL et al.
4 CONCLUDING REMARKS
The quality by design principle determined by the FDA
was applied to the early process steps of a CHO cell cultiva-
tion. Inoculum expansion process parameters were com-
piled and potential risks were assessed by failure mode
and effect analysis. The impact of selected parameters and
their interactionswere investigated using a design of exper-
iments approach in scaled down shake flasks. Multivari-
ate data analysis was used to analyse the experimental
data and calculate regression models fitting to the mea-
sured responses. Analysis of the effect- and response con-
tour plots identified the passage duration as a key process
parameter and its interaction effects with the initial pas-
sage viable cell density as a crucial part of the studied pro-
cess. It also showed that the parameters in the inoculum
expansion have a critical impact on later production pro-
cess performance.
A reduced MTX concentration and passage duration
improved the overall viability and growth rate of the inocu-
lum expansion and the production process. Additionally,
an opposite effect of the studied process parameters on the
specific productivity was observed, which still could not
compensate the discussed negative coefficients in terms of
total mAb production. Further analysis of the responses
resulted in the definition of a design space for the stud-
ied parameters. It showed the acceptable working range
for the process, which could be expanded with decreased
MTX concentration. Furthermore, it was shown to be
robust for a mean initial passage viable cell density, while
the optimum for the passage duration was found at the
experimentally possible minimum. Based on these results,
the early process steps were assessed as a critical part
of the process and should consequently be investigated
and analysed for newly developed processes and subse-
quently monitored and controlled using appropriate PAT
possibilities.
Leading forward, the findings of this study will be con-
nected to parameter effects of the production process to
further increase the understanding of the process. In the
course of those future studies, experiments will be carried
out using the Ambr R© microbioreactor platforms by Sar-
torius Stedim. In order to achieve further insights, prod-
uct quality attributes, namely the bioactivity, glycosylation
and charge variants of the produced mAb will be taken
into account. Thereby, this study is considered to be the
first step towards a full process characterization regarding
QbD principles, highlighting the importance of early pro-
cess understanding and investigation.
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